Daniel Christ

Dr Christ is Head of Antibody Therapeutics and Director of the Centre for Targeted Therapy at the Garvan Institute of Medical Research in Sydney, Australia.

Dr Christ was educated at the Swiss Federal Institute of Technology (ETH) and at Cambridge University, where he worked at the MRC Laboratory of Molecular Biology with Nobel Laureate Sir Gregory Winter, a pioneer of the British biotechnology industry. At Cambridge, Dr Christ and Sir Gregory developed monoclonal antibody technology, in the field of phage display and single domain antibodies. Dr Christ was elected a Fellow of Trinity College (Cambridge University) at age 29 and was involved in the foundation of Domantis Ltd (sold to GSK for £230 million in 2006).

Dr Christ joined the Garvan in 2007 as Head of Antibody Therapeutics, to translate structural and genomic advances into drug candidates and treatments for cancer and inflammatory conditions. Dr Christ is particularly well known for using both in vitro and in vivo selection strategies for generating antibodies with superior biophysical and targeting properties. His contributions have been recognised by multiple prizes and appointments, including the NHMRC Excellence award, and by the award of more than 15 competitive research grants from the NHMRC and ARC in recent years.